A study from the University of Maryland, Baltimore County (UMBC), published in Nature Communications, reveals how ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells—an advance ...

Glioma remains one of the most challenging malignancies of the central nervous system, characterized by a highly ...

Viruses are typically described as tiny, perfectly geometric shells that pack genetic material with mathematical precision, ...

Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...

Houston Methodist Research Institute is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) and leading scientific institutions in the Republic of Korea to develop what could ...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, and ...

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex moleculesSEATTLE--(BUSINESS WIRE)--As drug ...

Piper Sandler 37th Annual Healthcare Conference December 2, 2025 8:30 AM ESTCompany ParticipantsJacqueline Shea - ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...